Cymbopogon citratus L. essential oil as a potential anti-biofilm agent active against antibiotic-resistant bacteria isolated from chronic rhinosinusitis patients
1
Issued Date
2024-01-01
Resource Type
ISSN
08927014
eISSN
10292454
Scopus ID
2-s2.0-85183359650
Journal Title
Biofouling
Rights Holder(s)
SCOPUS
Bibliographic Citation
Biofouling (2024)
Suggested Citation
Khosakueng M., Taweechaisupapong S., Boonyanugomol W., Prapatpong P., Wongkaewkhiaw S., Kanthawong S. Cymbopogon citratus L. essential oil as a potential anti-biofilm agent active against antibiotic-resistant bacteria isolated from chronic rhinosinusitis patients. Biofouling (2024). doi:10.1080/08927014.2024.2305387 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/95826
Title
Cymbopogon citratus L. essential oil as a potential anti-biofilm agent active against antibiotic-resistant bacteria isolated from chronic rhinosinusitis patients
Corresponding Author(s)
Other Contributor(s)
Abstract
Chronic rhinosinusitis (CRS) is long-term inflammation of the sinuses that can be caused by infection due to antibiotic-resistant bacteria. Biofilm developed by microbes is postulated to cause antibiotic treatment failure. Thus, the anti-biofilm activities of seven Thai herbal essential oils (EOs) against antibiotic-resistant bacteria isolated from CRS patients was investigated. Lemongrass (Cymbopogon citratus L.) EO showed the most effective antibiofilm activity against Klebsiella pneumoniae, Pseudomonas aeruginosa and Staphylococcus epidermidis grown as biofilm. GC-MS analysis found that myrcene was the major bioactive compound. Pretreatment with lemongrass EO significantly inhibited biofilm formation of all bacterial strains in more than 50% of cases. Furthermore, confocal microscopy analysis revealed the biofilm-disrupting activity of lemongrass EO against the biofilm matrix of all these bacterial species and also increased P. aeruginosa swarming motility with no toxicity to human cells. These results suggest that lemongrass EO has promising clinical applications as an anti-biofilm agent for CRS patients.